World's First Endologix Powerlink System Procedures Performed with Visiflex SurePass Delivery System
April 12 2007 - 2:27PM
Business Wire
Endologix, Inc. (Nasdaq: ELGX) today announced the first three
successful implantations of the Powerlink� endoluminal stent graft
(ELG) incorporating the Visiflex SurePass Delivery System�. The
Visiflex SurePass is the Company�s next-generation delivery device
that allows physicians continued guidewire access to the
contralateral limb of the unibody Powerlink ELG device. The first
procedure was completed at William Beaumont Hospital in Royal Oak,
Mich., and two additional procedures were completed at the Arizona
Heart Hospital in Phoenix, Ariz. Venkatesh G. Ramaiah, M.D.,
Director of Vascular and Endovascular Research at the Arizona Heart
Institute, reported, �The SurePass Delivery System further improves
upon a delivery technology that is already state-of-the-art in
terms of ease of deployment.� Grayson Wheatley III, M.D., from the
Arizona Heart Institute, remarked, �It exceeded my expectations and
in this particular case facilitated access to a difficult
contralateral limb in a tortuous anatomy.� O. W. Brown, M.D., from
the William Beaumont Hospital, commented, �The technology performed
beyond my expectations and I believe the SurePass will further
simplify and broaden the applications for Powerlink.� The Visiflex
SurePass Delivery System replaces the contralateral limb wire with
a hollow guidewire capable of accommodating a standard 0.014
guidewire. The physician can insert the guidewire prior to limb
deployment in order to control and maintain access. In patients
with complex iliac anatomy physicians often perform adjunctive
balloon angioplasty or deliver an extension which requires the use
of a guidewire. �This is a significant improvement to the Powerlink
System�s design with a focus on upgrading and simplifying the
procedure, giving users greater confidence to expand the universe
of treatable patients,� said Paul McCormick, president and CEO of
Endologix. �This is an example of what a company can accomplish
with strong clinical collaboration and strength of purpose.� About
Endologix Endologix, Inc. develops and manufactures minimally
invasive treatments for vascular diseases. Endologix�s Powerlink
System is an endoluminal stent graft (ELG) for treating abdominal
aortic aneurysms (AAA). AAA is a weakening of the wall of the
aorta, the largest artery in the body, resulting in a balloon-like
enlargement. Once AAA develops, it continues to enlarge and, if
left untreated, becomes increasingly susceptible to rupture. The
overall patient mortality rate for ruptured AAA is approximately
75%, making it the thirteenth leading cause of death in the U.S.
Additional information can be found on Endologix�s Web site at
www.endologix.com.
Endologix (NASDAQ:ELGX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Endologix (NASDAQ:ELGX)
Historical Stock Chart
From Sep 2023 to Sep 2024